Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone.
Sanne Ten HoornDirkje W SommeijerFaye ElliottDavid FisherTim R de BackAnne TrinhLianne KoensTim MaughanJenny F SeligmannMatthew T SeymourPhil QuirkeRichard AdamsSusan D RichmanCornelis J A PuntLouis VermeulenPublished in: British journal of cancer (2021)
The subtype-specific efficacy of anti-EGFR therapy is dependent on the chemotherapy backbone. This may provide the possibility of subtype-specific treatment strategies for a more optimal use of anti-EGFR therapy.